MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

MAIA Biotechnology, Inc.AMEX: MAIA

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets rises 197.7% from a year ago

Total assets stood at $35.32M at the end of Q1 FY2026, up 197.7% from a year earlier and up 264.0% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.

Context

  • Total assets increased in 1 of the last 3 fiscal years.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +197.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.32M+264.0% QoQ
Last fiscal yearDec 2025
$9.7M-4.4% YoY
Year agoMar 2025
$11.86M+197.7% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+197.7%——
1 year-4.4%——
3-year CAGR-6.9%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
9.7M USD
Year-over-year change
-4.4%
4-year CAGR
-3.8%

Total Assets vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's Mar 2026 total assets of $35.32M is the 3rd highest of the 7 companies compared; the peer median is $17.7M.
  • Its year-over-year change of +197.7% is the highest of 7, against a peer median of -16.0%.
  • Over three fiscal years its annual growth of -6.9% compares with a peer median of -10.6%.
MAIA Competitors Peer median
Total Assets for MAIA and competitors
Company Period Latest balance YoY 3-year CAGR
CELUCelularity Inc.Dec 2025$107.33M -19.1%-35.6%
VERUVeru Inc.Mar 2026$43.08M +31.9%-39.6%
MAIAMAIA Biotechnology, Inc.Mar 2026$35.32M +197.7%-6.9%
PYPDPolyPid Ltd.Mar 2026$19.16M +13.7%-4.9%
ANVSAnnovis Bio, Inc.Mar 2026$16.24M -39.2%-16.4%
RNXTRenovoRx, Inc.Mar 2026$13.96M -12.8%+3.7%
LTRNLantern Pharma Inc.Mar 2026$7.22M -65.8%+472.4%
Peer median (excluding MAIA) $17.7M-16.0%-10.6%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.57M10.95M7.15M9.6M8.66B
Short-term Investments00000
Net Receivables43.67K302.79K144.68K77.35K0
Inventory00000
Other Current Assets(43.67K)554.32K268.68K473.83K(8.65B)
Total Current Assets10.67M11.81M7.56M10.15M9.7M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets654.7K214K2.8K2.8K2.8K
Total Non-current Assets654.7K214K2.8K2.8K2.8K
Total Assets11.33M12.02M7.57M10.16M9.7M
Account Payables960.4K1.17M1.64M1.51M2.04M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities496.02K1.09M1.61M941.1K1.2M
Total Current Liabilities2.15M3.27M4.94M3.83M5.84M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0245.34K2.15M2.69M1.49M
Total Non-current Liabilities0245.34K2.15M2.69M1.49M
Total Liabilities2.15M3.51M7.09M6.52M7.33M
Common Stock7581.1K1.7K2.62K3.86K
Retained Earnings(28.44M)(44.21M)(63.98M)(87.23M)(109.63M)
Accumulated OCI0(15.97K)(16.26K)(30.62K)(50.23K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity9.18M8.51M477.51K3.63M2.38M
Total Debt00000
Net Debt(10.57M)(10.95M)(7.15M)(9.6M)(8.66B)

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.